Lv1
38 积分 2022-05-24 加入
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
5天前
已完结
In vivo CAR T cell engineering: design principles and open questions
6天前
已完结
In Vivo CAR T Cells Deliver Deep Responses in Myeloma
6天前
已完结
Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma
14天前
已完结
Influence of Clonal Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts on Progression and Survival in Multiple Myeloma Patients After Autologous Peripheral Blood Stem Cell Transplantation in Long-term Observation
14天前
已完结
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)
1个月前
已完结
Renal Pathology Society/International Kidney and Monoclonal Gammopathy Research Group consensus on pathologic definitions and terminology of monoclonal gammopathy–associated kidney lesions
1个月前
已完结
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
1个月前
已完结
Diagnostic Challenges of Acute Kidney Injury in a Patient With High-Risk Multiple Myeloma: A Quiz
1个月前
已关闭
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference
1个月前
已完结
皖公网安备34019202002308
